High-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer.
ADT is usually given for 18 to 24 months, but it can cause side effects that may affect quality of life.
Some people with high-risk prostate cancer may do just as well with a shorter course of ADT. This study will identify people who are most likely to benefit from shorter treatment using imaging scans and tumor tests. It will then evaluate whether a shorter course of ADT works as well as the standard treatment while reducing long-term side effects.
• Able to understand and sign informed consent form (ICF);
Males aged ≥ 18 years;
Histologically confirmed adenocarcinoma of the prostate;
PTEN-proficient tumor confirmed by CLIA-certified immunohistochemistry (IHC);
• Prior local or systemic therapy for prostate cancer (e.g. ADT, chemotherapy or novel Androgen Receptor Inhibitors [ARIs]);
PSMA-PET positive nodal or distant metastases;
PTEN loss or equivocal by IHC (at least more than 50%);
Evidence of nodal or distant metastases on conventional imaging;
Dr. Tamim Niazi
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Sponsor institution